| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
RTC-30 targets cancer cell proliferation through its phenothiazine scaffold. The optimized phenothiazine structure with a hydroxylated linker enhances oral bioavailability and anticancer activity. The compound inhibits lung adenocarcinoma cell growth with a GI₅0 of 15 microM. The precise molecular target of RTC-30 is not fully elucidated in the available literature, but phenothiazines are known to interact with various cellular targets including dopamine receptors, calmodulin, and kinases.
|
|---|---|
| ln Vitro |
RTC-30 (0-40 μM; 48 hours) inhibits H1650 lung cancer cells from growing when applied at a GI50 of 15 μM [1].
In vitro, RTC-30 inhibits H1650 lung adenocarcinoma cell growth with a GI₅0 of 15 microM. The compound demonstrates potent anti-cancer properties in cell-based assays. The optimized phenothiazine structure with a hydroxylated linker enhances its activity compared to earlier phenothiazine derivatives. Detailed IC₅0 values against other cancer cell lines are not extensively documented in the available literature. |
| ln Vivo |
In vivo activity data for RTC-30 are not extensively documented. The compound is formulated with a hydroxylated linker that confers increased oral bioavailability (F), suggesting potential for in vivo efficacy. The compound is an optimized phenothiazine developed for anticancer research. Further in vivo efficacy studies in xenograft models would be needed to confirm antitumor activity and characterize pharmacokinetic properties.
|
| Enzyme Assay |
The in vitro anti-proliferative assay uses cancer cell lines such as H1650 lung adenocarcinoma cells. Cells are cultured in appropriate medium and treated with RTC-30 at various concentrations for 48 hours or longer. Cell viability is measured using MTT, CellTiter-Glo, or sulforhodamine B (SRB) assays. GI₅0 values are calculated from dose-response curves. Cells are maintained under standard culture conditions (37degC, 5% CO2) and experiments are typically performed in triplicate.
|
| Cell Assay |
Cell viability assay [1]
Cell Types: H1650 lung adenocarcinoma cells Tested Concentrations: 0 μM, 1 μM, 10 μM, 20 μM, 30 μM, 40μM Incubation Duration: 48 hrs (hours) Experimental Results: Inhibition of the growth of H1650 lung adenocarcinoma cells. For in vitro cell-based assays, H1650 lung adenocarcinoma cells or other cancer cell lines are seeded in 96-well plates and cultured overnight. RTC-30 is added at various concentrations (0-40 microM) and cells are incubated for 48 hours. Cell viability is measured using standard proliferation assays. The GI₅0 is calculated as the concentration required to inhibit cell growth by 50% compared to untreated controls. Experiments include appropriate positive and negative controls and are performed in triplicate. |
| Animal Protocol |
In vivo animal studies for RTC-30 would typically involve xenograft mouse models using H1650 or other cancer cell lines. Tumor-bearing mice are administered RTC-30 orally at various doses (leveraging its enhanced oral bioavailability). Tumor volume is measured periodically using calipers, and tumor growth inhibition is assessed relative to vehicle-treated controls. At study termination, tumors are harvested for histopathological analysis and assessment of proliferation markers. Pharmacokinetic studies may also be performed.
|
| ADME/Pharmacokinetics |
RTC-30 contains a hydroxylated linker that confers increased oral bioavailability. The compound has molecular weight 492.51 and molecular formula C24H23F3N2O4S. It is soluble in DMSO and typically formulated for oral administration in research settings. Purity is typically ≥99%. The compound is supplied as a high-purity white to off-white solid and as a ready-to-use 10 mM solution in DMSO for in vitro studies. Storage at -20degC is recommended.
|
| Toxicity/Toxicokinetics |
Toxicological data for RTC-30 are not well characterized in the public domain. As a research chemical, standard safety precautions should be observed. The compound is for laboratory use only and not intended for human therapeutic applications. Phenothiazine derivatives as a class have known pharmacological effects including dopamine receptor antagonism. Comprehensive toxicity profiling would be required for therapeutic development.
|
| References | |
| Additional Infomation |
RTC-30 (CAS# 1423077-95-5) is an optimized phenothiazine compound with anticancer potency. It contains a hydroxylated linker that increases oral bioavailability. The compound inhibits H1650 lung adenocarcinoma cell growth with a GI₅0 of 15 microM. It is used in anticancer research and is not approved for clinical use.
|
| Molecular Formula |
C24H23F3N2O4S
|
|---|---|
| Molecular Weight |
492.510635614395
|
| Exact Mass |
492.133
|
| CAS # |
1423077-95-5
|
| PubChem CID |
71263372
|
| Appearance |
White to off-white solid powder
|
| LogP |
5.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
34
|
| Complexity |
728
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
S(C1C=CC(=CC=1)OC(F)(F)F)(NC[C@@H](CN1C2C=CC=CC=2CCC2C=CC=CC1=2)O)(=O)=O
|
| InChi Key |
HNXBILKEHPSDSB-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C24H23F3N2O4S/c25-24(26,27)33-20-11-13-21(14-12-20)34(31,32)28-15-19(30)16-29-22-7-3-1-5-17(22)9-10-18-6-2-4-8-23(18)29/h1-8,11-14,19,28,30H,9-10,15-16H2/t19-/m0/s1
|
| Chemical Name |
N-[(2R)-3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-2-hydroxypropyl]-4-(trifluoromethoxy)benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~15 mg/mL (~30.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.5 mg/mL (3.05 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 15.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.5 mg/mL (3.05 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 15.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.5 mg/mL (3.05 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0304 mL | 10.1521 mL | 20.3042 mL | |
| 5 mM | 0.4061 mL | 2.0304 mL | 4.0608 mL | |
| 10 mM | 0.2030 mL | 1.0152 mL | 2.0304 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
